Dr. Marty Makary noted it had "record speed approval," the fastest approval of any gene therapy device combination in U.S.

Three 2026 Breakthrough Prize winners reflect on developing Luxturna, a gene therapy that treats blindness caused by rare ...

CRISPR gene therapy increases haemoglobin and fetal haemoglobin in sickle cell disease, reducing vaso occlusive events in ...

Comprehending the spate of recent rejections in the cell and gene therapy space may require looking no further than ...

EQUIGENE Therapeutics, a new spin-off biotech anchored by world-class hematology experts, marks a pivotal step in the UAE’s ...

The Food and Drug Administration accepted Opus Genetics's investigational gene therapy into its Rare Disease Evidence Principles program, the company said Monday. The clinical-stage biopharmaceutical ...

The therapy is part of a plan to develop gene therapies that can be efficiently delivered at lower doses, enabling them to be ...

After some tough feedback from the FDA on the path forward for its lead gene therapy, Passage Bio has launched a strategic ...

Latus Bio, Inc. (Latus), a biotechnology company engineering scalable gene therapies for broader patient populations, today ...

Commercial Cell and Gene Therapy Revenue -- $9.1 million, up 26% year over year, reflecting growth in therapies supported.

First quarter revenue grew 16% year-over-year to $47.8 million Commercial cell and gene therapy (CGT) revenue grew 26% year-over-year to $9.1 million, reflecting ...

Globally, and particularly in the U.S., new frameworks are creating genuine opportunities for earlier collaboration.